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Background: Lung clearance index (LCI) is a measure of abnormal ventilation distribution derived from the
multiple breath inert gas washout (MBW) technique. We aimed to determine the clinical utility of LCI in non-CF
bronchiectasis, and to assess two novel MBW parameters that distinguish between increases in LCI due to specific
ventilation inequality (LCIvent) and increased respiratory dead space (LCIds).
Methods: Forty-three patients with non-CF bronchiectasis and 18 healthy control subjects underwent MBW using
the sulphur hexafluoride wash-in technique, and data from 40 adults with CF were re-analysed. LCIvent and LCIds
were calculated using a theoretical two-compartment lung model, and represent the proportional increase in LCI
above its ideal value due to specific ventilation inequality and increased respiratory dead space, respectively.
Results: LCI was significantly raised in patients with non-CF bronchiectasis compared to healthy controls (9.99 versus
7.28, p < 0.01), and discriminated well between these two groups (area under receiver operating curve = 0.90, versus 0.83
for forced expiratory volume in one second [% predicted]). LCI, LCIvent and LCIds were repeatable (intraclass correlation
coefficient > 0.75), and correlated significantly with measures of spirometric airflow obstruction.
Conclusion: LCI is repeatable, discriminatory, and is associated with spirometric airflow obstruction in patients
with non-CF bronchiectasis. LCIvent and LCIds are a practical and repeatable alternative to phase III slope analysis
and may allow a further level of mechanistic information to be extracted from the MBW test in patients with
severe ventilation heterogeneity.
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Non-cystic fibrosis (CF) bronchiectasis is a chronic sup-
purative lung disease caused by a range of underlying
conditions, which is increasing in prevalence [1], and
which imposes a significant burden of morbidity and
healthcare costs. In the United States alone, annual
healthcare costs for bronchiectasis are estimated as $630
million [2]. The causes of non-CF bronchiectasis are di-
verse, and include autoimmune disease, primary ciliary dys-
kinesia, allergic bronchopulmonary aspergillosis, immune
deficiency and childhood respiratory infection [3]. Regard-
less of the underlying cause, the pathogenesis is thought to
involve a vicious cycle of bacterial colonisation, neutrophilic* Correspondence: sg330@le.ac.uk
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unless otherwise stated.airway inflammation, airway damage and mucus stasis [3].
The evidence base for the treatment of non-CF bronchiec-
tasis lags well behind that of CF, but this is expected to
change in the near future as a number of non-CF bron-
chiectasis research registries and clinical trials are
actively enrolling patients at present [4]. Such clinical
trials will require robust physiological outcome measures in
order to provide objective measures of improvement in
lung function.
Multiple breath inert gas washout (MBW) is a tech-
nique for quantifying ventilation heterogeneity, the
uneven distribution of ventilation [5]. This is an early
feature of obstructive airway diseases such as asthma
[6], chronic obstructive pulmonary disease [6] and cys-
tic fibrosis (CF) [7]. A comprehensive standardisation
document for the performance of inert gas washout
has been recently published [8]. Lung clearance indexLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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parameter, and is defined as the cumulative expired
volume at the point where end-tidal inert gas concen-
tration falls below 1/40th of the original concentration,
divided by the functional residual capacity (FRC). LCI
has been shown to be both discriminatory and repeat-
able in patients with CF [7], and is increasingly being
used as an outcome measure in clinical trials of CF
therapies [11-13]. A recent study has shown that LCI is
repeatable in patients with non-CF bronchiectasis, and
correlates with computed tomography bronchiectasis
severity scores [14].
Although LCI has been shown to be a robust and re-
peatable measurement in patients with CF and non-CF
bronchiectasis, it also represents a simplification of the
washout process since it is essentially determined by
data points at the start and end of the washout curve
only. From a theoretical standpoint, LCI may be in-
creased by two distinct mechanisms, namely (i) unequal
convective ventilation between relatively large lung units
subtended by proximal conducting airways (convection-
dependent inhomogeneity), and (ii) increased respiratory
dead space, which is thought to be underpinned by
diffusion-dependent gas mixing inefficiencies (diffusion-
convection-dependent inhomogeneity) [15]. The only
published method for separating out these mechanisms
is the analysis of phase III slopes, yielding the parame-
ters Scond (conductive ventilation heterogeneity index)
and Sacin (acinar ventilation heterogeneity index) [16].
This technique was developed from elegant clinical and
modelling studies in healthy adult subjects [17]. How-
ever, the use of these parameters is problematic in pa-
tients with the most severe ventilation heterogeneity,
such as those with advanced CF lung disease [18], both
from a practical standpoint (the requirement for con-
trolled 1 L breaths) and because the modelling may not
be directly applicable in those with severe ventilation
heterogeneity. To overcome this, modified versions of
these parameters (Scond* and Sacin*) have recently been
proposed for use in such patients [19]. There remains a
need however for a reliable and repeatable method of
extracting mechanistic information from washout curves,
which has been developed for, and can be applied in, those
with more severe disease.
The primary aim of this study was to determine
whether or not ventilation heterogeneity is a significant
feature of non-CF bronchiectasis, and whether LCI may
have potential as an outcome measure in this group of
patients. A further aim of the study was to extend
currently available measures of ventilation heterogeneity
by developing novel parameters that would distinguish
between specific ventilation inequality (LCIvent) and in-
creased respiratory dead space (LCIds) as a cause of
increased LCI. LCIvent and LCIds would be expected toprobe similar mechanisms of ventilation heterogeneity
to Scond and Sacin, respectively, but without the potential
drawbacks of phase III slope analysis, and with the ad-
vantage of being directly linked to LCI.
We hypothesised that:
i) Non-CF bronchiectasis is characterised by increased
LCI, LCIvent and LCIds compared to healthy control
subjects.
ii) LCI is related to other measures of disease severity
in CF and non-CF bronchiectasis, namely the degree
of spirometric airflow obstruction and the presence
or absence of chronic bacterial colonisation.
iii) LCI is repeatable in patients with non-CF
bronchiectasis, and is superior to spirometry for
distinguishing between patients with non-CF
bronchiectasis and healthy controls.
Methods
Subjects
Forty-three adult patients with non-CF bronchiectasis
were recruited from the respiratory out-patient clinics at
Glenfield Hospital. Bronchiectasis was diagnosed by high
resolution computed tomography, and all scans were
reported by a Consultant Radiologist to confirm the diag-
nosis. Eighteen healthy non-smoking control subjects with
no history of respiratory symptoms were recruited through
local advertising. The study was approved by the National
Research Ethics Committee (East Midlands – Leicester),
and all participants gave their written informed consent. As
a disease comparator group, MBW data from 40 adults
with CF who took part in a previous observational study [7]
were re-analysed. This study was approved by the Lothian
Research and Ethics Committee and all participants gave
their written informed consent.
Clinical characterisation of bronchiectasis patients
Demographic details and a full medical history were ob-
tained from each patient. Sputum samples were obtained
for bacterial culture, and sputum culture results during
the previous year were recorded to assess for chronic
bacterial colonisation, defined as isolation of the same
microorganism on sputum culture on at least two occa-
sions during the previous year. Participants underwent
spirometry and measurement of lung volumes using he-
lium dilution according to American Thoracic Society/
European Respiratory Society guidelines [20,21].
Multiple breath washout test
MBW was performed in triplicate at a single visit, using
the method described by Horsley et al. [7]. Participants
wore a nose clip and breathed a known concentration
(0.2%) of an inert and non-absorbed gas, sulphur hexa-
fluoride (SF6), via a mouthpiece connected to an Innocor
Table 1 Multiple breath washout parameters
Method of calculation Mechanism of ventilation
heterogeneity
LCI Analysis of basic washout
curve
Summary measure of overall
ventilation heterogeneity
LCIvent Two-compartment model Specific ventilation inequality:
convection-dependent
LCIds Two-compartment model Dead space contribution:
diffusion-convection-dependent
Scond Phase III slope analysis Convection-dependent
Sacin Phase III slope analysis Diffusion-convection-
dependent
Scond* Phase III slope analysis
(modified)
Convection-dependent
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Denmark), until the expired concentration in their exhaled
breath reached a steady state (wash-in phase). Participants
with non-CF bronchiectasis maintained a steady respiratory
rate of approximately 12 breaths per minute, and a constant
tidal volume of 1 L, using a real-time visual display of in-
spired volume as a guide. Patients with CF in the previously
published cohort [7] were not generally able to follow this
protocol, and washout tests were therefore performed
during relaxed tidal breathing in this group. Following
completion of wash-in, participants were rapidly switched
to breathing room air during expiration and continued the
same pattern of breathing (washout phase). Washout con-
tinued until the end-tidal concentration of expired SF6 fell
below 1/40th of the original concentration (ie. < 0.005%)
for three consecutive breaths.
Analysis of washout curves
Washout curves were analysed using custom software writ-
ten with TestPoint (Measurement Computing Corporation,
Norton, Massachusetts, USA). FRC was calculated by divid-
ing the total volume of SF6 expired during the washout by
the difference between the SF6 concentrations at the begin-
ning and end of the washout period [22]. LCI was calcu-
lated as the cumulative expired volume at the point where
the end-tidal concentration of expired SF6 fell below 1/40th
of the original concentration, divided by the FRC [9]. Scond/
Sacin and Scond*/Sacin* were calculated as described by
Verbanck et al. [16,19]. The derivation of the novel
parameters LCIvent and LCIds is described in detail in the
Additional files 1,2,3,4,5,6,7 and 8. Briefly, washout curves
were fitted to a theoretical two-compartment lung model.
The output parameters of the model were (i) the ratio of
the specific ventilations of the two compartments, and (ii)
the effective respiratory dead space. These parameters were
then utilised to derive:
i. LCIvent – The proportional increase in LCI above its
ideal value due to specific ventilation inequality.
ii. LCIds – The proportional increase in LCI above its
ideal value due to increased respiratory dead space.
Table 1 summarises the MBW parameters calculated
in this study and their physiological interpretation.
Statistical analysis
Statistical analyses were performed using SPSS Version
20 (IBM Corporation, Somers, New York, USA) and
Prism 6 (GraphPad Software Inc., La Jolla, California,
USA). Between-group comparisons were performed
using Student’s T test or one-way analysis of variance
for continuous data and the Chi-squared test for pro-
portions, with the threshold for statistical significance
set at p < 0.05. Repeatability of MBW parameters wasassessed using the intraclass correlation coefficient
(ICC) across triplicate measurements, using a two-
way mixed model. Correlations between variables were
assessed using Pearson’s correlation coefficient (R). A
generalised linear model was used to assess whether
the relationship between LCI and spirometric airflow
obstruction differed between the two disease groups.
Areas under receiver operating characteristic (ROC)
curves were used to assess the discriminatory ability of
physiological parameters.Results
Clinical characteristics
The cohort of patients with non-CF bronchiectasis com-
prised 19 men and 24 women with a mean (standard de-
viation [SD]) age of 67.4 (7.3) years. The group included
25 never smokers, 17 ex-smokers and 1 current smoker.
The median (range) pack-year smoking history of the
ex- and current smokers was 17.5 (1 – 140). Out of the
43 patients, a previous history of tuberculosis was elic-
ited in 2 patients, childhood pneumonia in 14 patients
and pertussis in 22 patients. Eleven patients had a history
of asthma, and four had a formal diagnosis of allergic
bronchopulmonary aspergillosis. Nineteen patients had
symptoms of gastroesophageal reflux disease and two had
inflammatory bowel disease. Twelve patients had an inflam-
matory arthritis and one had yellow nail syndrome. Twelve
patients were chronically colonised with Haemophilus
influenzae, three patients with Pseudomonas aeruginosa,
two patients with Staphylococcus aureus and two patients
with coliforms.
The CF group comprised 20 men and 20 women with
a mean (SD) age of 28.7 (9.8) years. Three CF patients
were ex-smokers (pack-year histories of 5, 15 and
24 years). Fifteen patients had chronic Pseudomonas aer-
uginosa colonisation as defined by Lee et al. [23], 29 had
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Nineteen patients had a severe genotype, defined as hav-
ing a class I or II mutation on both chromosomes, and
16 had a mild genotype, defined as having a class III, IV
or V mutation on at least one chromosome. The geno-
type was incomplete in 5 patients.
Group comparisons
Table 2 shows physiological data across all three groups.
Patients with bronchiectasis and CF both displayed spi-
rometric airflow obstruction, with significantly reduced
forced expiratory volume in one second/forced vital cap-
acity (FEV1/FVC) ratio compared to healthy controls.
LCI, LCIvent and LCIds were all significantly greater in
bronchiectasis patients compared to controls, and sig-
nificantly greater in CF patients compared to both con-
trols and bronchiectasis patients (see Figure 1).
Correlations between spirometric airflow obstruction and
lung clearance index
Figure 2 shows correlations between the FEV1 (% pred.)
and LCI in patients with bronchiectasis and patients
with CF. In both cases, there was a highly significant








patients (n = 43)
Age (years)‡‡‡‡ 48.3 (3.9) 28.7 (1.5)#### 67.4 (1.1)####, ¥¥¥¥
Sex (% male) 50 50 44
BMI (kg/m2)‡‡‡‡ 26.8 (1.2) 22.9 (0.5)## 27.1 (0.7)¥¥¥¥
FEV1 (% pred.)
‡‡‡‡ 113.3 (4.8) 65.9 (3.4)#### 82.0 (3.8)####, ¥¥
FVC (% pred.)‡‡‡‡ 117.2 (5.6) 84.5 (3.0)#### 96.1 (3.4)##, ¥
FEV1/FVC (%)
‡‡‡‡ 80.9 (1.0) 65.9 (1.8)#### 68.4 (1.7)####
FRCmbw (L)
‡‡ 2.52 (0.19) 1.99 (0.09)# 2.48 (0.10)¥¥
LCI‡‡‡‡ 7.28 (0.27) 13.17 (0.56)#### 9.99 (0.31)##, ¥¥¥¥
LCIvent
‡‡‡‡ 1.20 (0.02) 1.65 (0.04)#### 1.42 (0.03)###, ¥¥¥¥
LCIds
‡‡‡‡ 1.13 (0.01) 1.40 (0.03)#### 1.27 (0.02)###, ¥¥¥¥
Scond (L
−1)‡‡‡‡ 0.033 (0.007) 0.131 (0.010)#### 0.064 (0.007)¥¥¥¥
Sacin (L
−1)‡‡‡‡ 0.118 (0.014) 0.509 (0.056)#### 0.373 (0.036)##
Scond* (L
−1)‡‡‡‡ 0.097 (0.009) 0.308 (0.034)#### 0.107 (0.010)¥¥¥¥
Sacin* (L
−1)‡‡‡‡ 0.090 (0.012) 0.446 (0.054)#### 0.355 (0.037)##
CF = cystic fibrosis; BMI = body mass index; FEV1 = forced expiratory volume in
one second; FVC = forced vital capacity; FRCmbw = functional residual capacity
from multiple breath washout; LCI = lung clearance index; LCIvent = specific
ventilation inequality component of lung clearance index; LCIds = dead space
component of lung clearance index. Data expressed as mean (standard error)
or percentages. Groups compared using one-way analysis of variance with
Bonferroni correction for multiple comparisons for parametric data, and the
Chi-squared test for proportions. Significant differences across groups denoted
‡‡(p < 0.01) or ‡‡‡‡(p < 0.0001). Significant differences compared to control
group denoted #(p < 0.05), ##(p < 0.01), ###(p < 0.001) or ####(p < 0.0001).
Significant differences between bronchiectasis and CF groups denoted
¥(p < 0.05), ¥¥(p < 0.01) or ¥¥¥¥(p < 0.0001).and LCI. However, the slope of the relationship between
the two variables differed significantly between the
groups. Patients with CF had a 0.13 unit increase in LCI
for every 1 percentage point reduction in FEV1 (% pred.),
whereas patients with bronchiectasis had a 0.05 unit
increase in LCI for every 1 percentage point reduction
in FEV1 (% pred.) (p < 0.0001). LCIvent and LCIds corre-
lated highly significantly with FEV1 (% pred.) in both
patients with non-CF bronchiectasis (R = −0.63 for
LCIvent, R = −0.60 for LCIds, p < 0.0001 for both ana-
lyses) and patients with CF (R = −0.78 for LCIvent,
R = −0.76 for LCIds, p < 0.0001 for both analyses).
There were significant correlations between LCIvent
and LCIds in both patient groups (R = 0.80, p < 0.0001
for non-CF bronchiectasis; R = 0.89, p < 0.0001 for CF).Multiple breath washout parameters and chronic
bacterial colonisation
Table 3 shows MBW and spirometric indices in patients
with CF in the presence and absence of chronic P. aerugi-
nosa colonisation, and in patients with non-CF bronchiec-
tasis in the presence and absence of chronic bacterial
colonisation. LCIds was significantly raised in CF patients
with chronic P. aeruginosa colonisation compared to those
without chronic colonisation (1.49 vs 1.34, p = 0.004).Within-visit repeatability and discriminatory ability
Table 4 shows the repeatability of MBW parameters in
patients with bronchiectasis and CF. Intraclass correl-
ation coefficients exceeded 0.75 for LCI, LCIvent and
LCIds in both disease groups. Sacin and Sacin* displayed
moderate or good repeatability, but Scond and Scond*
were poorly repeatable in both disease groups. Figure 3
shows ROC curves illustrating the discriminatory ability
of LCI and FEV1 (% pred.) for distinguishing between
healthy controls and patients with non-CF bronchiec-
tasis. The area under the ROC curve was 0.90 for LCI
and 0.83 for FEV1 (% pred.). Areas under the ROC curve
for LCIvent and LCIds were 0.88 and 0.89, respectively.
Figure 4 shows graphs of FEV1 standardised residuals
against LCI, LCIvent and LCIds in patients with non-CF
bronchiectasis. The lower limit of normal for FEV1 was
defined as 1.645 standard deviations below the predicted
value, while the upper limits of normal for LCI, LCIvent
and LCIds were defined as the mean + 1.645 standard de-
viations in the healthy control group. Thirty out of 43
patients had an FEV1 within the normal range, and of
these, LCI, LCIvent and LCIds were high in 12, 10 and 10
patients, respectively. Conversely, there were no patients
who had an FEV1 below the normal range who did not
also have a raised LCI and LCIvent, and only one pa-
tient who had an FEV1 below the normal range with a
normal LCIds.
Figure 1 Multiple breath washout parameters across groups. CF = cystic fibrosis; LCI = lung clearance index; LCIvent = specific ventilation
inequality component of lung clearance index; LCIds = dead space component of lung clearance index. LCI (Panel A), LCIvent (Panel B) and
LCIds (Panel C) are compared across groups. Error bars denote mean +/- standard error.
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We have shown that LCI, and the novel parameters
LCIvent and LCIds, are significantly raised in patients
with non-CF bronchiectasis compared to controls, and
that these parameters correlate strongly with spirometric
markers of airflow obstruction. LCI, LCIvent and LCIds
display good within-visit repeatability in patients with
non-CF bronchiectasis, and superior discriminatory abil-
ity for distinguishing bronchiectasis patients from con-
trols compared to FEV1. Moreover, these parameters are
abnormally raised in a significant proportion of non-CF
bronchiectasis patients with a normal FEV1. These find-
ings suggest that MBW parameters may have potential
as markers of disease severity in patients with non-CF
bronchiectasis, and may be indicators of incipient air-
flow obstruction, although longitudinal studies are re-
quired to test this hypothesis. Further studies are also
required to determine the between-visit variability and
minimal clinically important difference of MBW param-
eters in patients with non-CF bronchiectasis, as well as
their responsiveness to therapeutic interventions.Figure 2 Correlations between lung clearance index and FEV1 (% pre
bronchiectasis (Panel A) and cystic fibrosis (Panel B). LCI = lung clearance
regression lines are shown, together with Pearson correlation coefficients.A major aim of this study was to develop novel
markers of ventilation heterogeneity that would distin-
guish between the two possible mechanisms of in-
creased LCI, namely specific ventilation inequality and
increased respiratory dead space. Previous studies have
used measures of the curvilinearity of the washout
curve as markers of specific ventilation inequality, but
these methods did not provide a formal estimate of the
respiratory dead space component [15,19]. Although in
healthy subjects it is thought that specific ventilation
inequality is the only mechanism of ventilation hetero-
geneity operative at the level of the proximal conduct-
ing airways, the situation is disease is far more
complex. Depending on the extent of airway damage
and obstruction, diffusion may not be neatly compart-
mentalised to the distal airways. An advantage of the
current method is that it does not pre-suppose an
anatomical location for the observed abnormalities in
ventilation heterogeneity, but concentrates on the
underlying mechanisms. This is particularly relevant
when dealing with those with more severe airflowdicted). Correlations are shown for patients with non-cystic fibrosis
index; FEV1 = forced expiratory volume in one second. Best-fit linear
Table 3 Physiological parameters in patients with and without chronic bacterial colonisation
Non-cystic fibrosis bronchiectasis Cystic fibrosis
No chronic colonisation Chronic colonisation No chronic PsA colonisation Chronic PsA colonisation
(n = 26) (n = 17) (n = 25) (n = 15)
FEV1 (% pred.) 86.1 (5.3) 75.6 (4.9) 69.7 (4.5) 59.6 (4.5)
FVC (% pred.) 101.7 (4.6) 87.5 (4.1)# 86.9 (3.6) 80.6 (5.5)
FEV1/FVC (%) 68.6 (2.4) 68.1 (2.4) 67.1 (2.5) 63.9 (2.5)
TLC (% pred.) 95.3 (3.1) 93.9 (4.0) - -
LCI 10.02 (0.36) 9.95 (0.57) 12.29 (0.72) 14.44 (0.85)
LCIvent 1.42 (0.03) 1.41 (0.05) 1.59 (0.05) 1.75 (0.05)
LCIds 1.27 (0.02) 1.26 (0.03) 1.34 (0.03) 1.49 (0.04)
##
Scond (L
−1) 0.058 (0.010) 0.072 (0.010) 0.122 (0.010) 0.132 (0.018)
Sacin (L
−1) 0.429 (0.053) 0.288 (0.038) 0.438 (0.070) 0.611 (0.093)
Scond* (L
−1) 0.102 (0.014) 0.115 (0.016) 0.284 (0.034) 0.294 (0.051)
Sacin* (L
−1) 0.412 (0.053) 0.268 (0.041) 0.376 (0.068) 0.553 (0.092)
PsA = Pseudomonas aeruginosa; FEV1 = forced expiratory volume in one second; FVC = forced vital capacity; TLC = total lung capacity; LCI = lung clearance index;
LCIvent = specific ventilation inequality component of lung clearance index; LCIds = dead space component of lung clearance index. Data expressed as mean
(standard error). Colonised and non-colonised groups within each disease cohort compared using Student’s T test. Significant differences between groups denoted
#(p < 0.05) or ##(p < 0.01).
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more, since the proximal and distal airways are not
independent of each other, and form a complex inter-
acting network [24], it is also unsurprising that we
noted a correlation between LCIvent and LCIds in both
patient groups. LCIvent and LCIds may however allow
subtle distinctions to be made in terms of mechanisms
of disease in airway diseases such as CF and non-CF
bronchiectasis. Indeed, we observed that CF patients
with chronic P. aeruginosa colonisation had increased
LCIds compared to those who did not, whereas LCIvent
did not differ significantly between the groups. This
extends the findings of Belessis et al. [25], who ob-
served that LCI was higher in children with CF whoTable 4 Within-visit repeatability of multiple breath
washout parameters








ICC = intraclass correlation coefficient; SD = standard deviation; CF = cystic
fibrosis; LCI = lung clearance index; LCIvent = specific ventilation inequality
component of lung clearance index; LCIds = dead space component of lung
clearance index.had P. aeruginosa colonisation compared to those who
did not. Our results suggest that this increase in LCI
may be driven predominantly by an increased respira-
tory dead space. Interestingly, neither MBW parame-
ters nor FEV1 (% pred.) differed significantly between
non-CF bronchiectasis patients with and without
chronic bacterial colonisation. Chronic colonisation in
our cohort was mainly with H. influenzae rather than
P. aeruginosa, and our data therefore concord with
previous observations that H. influenzae, unlike P. aer-
uginosa, is not associated with faster lung function
decline in non-CF bronchiectasis [26]. The reduced
FVC (% pred.) we observed in non-CF bronchiectasis
patients with chronic colonisation was not associated
with an abnormally low TLC (% pred.), and therefore
did not represent a true restrictive deficit.
Previous attempts to apply phase III slope analysis in
CF were less successful than in reports from other dis-
ease groups, because of both poor repeatability and re-
liance of the original method on a strict 1 L breathing
protocol [18]. Although it relies on a relaxed and
repeatable breathing pattern, the current method does
not require strict breath volume control, something pa-
tients often find harder to maintain than well-trained vol-
unteers. In addition, LCIvent and LCIds showed superior
repeatability to phase III slope parameters, in particular to
Scond and Scond*. This is an important attribute if these
measures are to be used to assess change over time, or in
response to therapeutic intervention.
A potential limitation of our study was that the disease
groups were not matched for age with the control group.
Figure 3 Receiver operating characteristic curves of lung clearance index and FEV1 (% pred.) for distinguishing between control
subjects and bronchiectasis patients. Receiver operating characteristic (ROC) curves are shown for lung clearance index (LCI) (Panel A) and
forced expiratory volume in one second percent predicted (FEV1 [% pred.]) (Panel B). Areas under ROC curves are 0.90 for LCI and 0.83 for FEV1
(% pred.).
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with non-CF bronchiectasis are in general older than
those with CF, and we therefore chose our control
group to be approximately intermediate in age between
the two disease groups. However, recently published
regression equations [27] indicate that the effects of
this on our results were likely to be modest – in par-
ticular, LCI is expected to increase by 0.0223 units per
year, so the 19-year difference in mean age between pa-
tients with bronchiectasis and healthy controls would
be predicted to cause a relatively small 0.43 difference
in LCI between the groups. Furthermore, the upper
limit of normal of LCI derived from our healthy con-
trol data was slightly higher than that reported in
previous studies using the same methodology [7], a
difference that may be explained by the older age of
our healthy cohort. Further studies are required to de-
rive age- and sex-dependent normative ranges for LCIFigure 4 Scatterplots of forced expiratory volume in one second st
parameters. LCI = lung clearance index; LCIvent = specific ventilation in
component of lung clearance index; FEV1 = forced expiratory volume in
against LCI (Panel A), LCIvent (Panel B) and LCIds (Panel C). Dotted lin
normal for LCI, LCIvent and LCIds.using the SF6 wash-in method, as have been published
for nitrogen washout [27].
In conclusion, we have shown that LCI, a marker of
impaired gas mixing derived from the MBW test, is sig-
nificantly raised in patients with non-CF bronchiectasis,
and that this elevation correlates with spirometric airflow
obstruction. LCI is repeatable and discriminatory in pa-
tients with non-CF bronchiectasis, and future studies are
now required to assess the prognostic significance of a
raised LCI in this patient group, as well as the potential util-
ity of this marker as an outcome measure in interventional
trials. The novel parameters LCIvent and LCIds are a prac-
tical and repeatable alternative to phase III slope analysis
and may allow a further level of mechanistic information to
be obtained from the MBW test without any additional de-
mand on the patient. They should be reported in conjunc-
tion with LCI in future observational and interventional
studies that incorporate the MBW technique.andardised residuals against multiple breath washout
equality component of lung clearance index; LCIds = dead space
one second; SR = standardised residuals. FEV1 SR are plotted
es denote the lower limit of normal for FEV1 and upper limits of
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Additional file 1: Derivation of the indices LCIvent and LCIds
(Additional files 2, 3, 4, 5, 6, 7 and 8).
Additional file 2: Figure E1. Washout curve from a healthy subject. Cet =
end-tidal SF6 concentration; TO = turnover number.
Additional file 3: Figure E2. Simulated washout curves with varying
specific ventilation inequality and effective respiratory dead space. Cet =
end-tidal SF6 concentration; TO = turnover number. Panel A shows
simulated washout curves with low (continuous line), intermediate (dashed
line) and high (dotted line) levels of specific ventilation inequality. Panel B
shows simulated washout curves with small (continuous line), intermediate
(dashed line) and large (dotted line) effective respiratory dead space.
Additional file 4: Figure E3. One-compartment lung model. VDanat =
anatomical dead space; VT = tidal volume; VA = alveolar volume; FRC =
functional residual capacity.
Additional file 5: Figure E4. Exponential decay curves. Single exponential
decay curves of the form y = 0.2 × e‒kx are shown with rate constants (k) of
0.2 (dotted line), 0.6 (dashed line) and 1.8 (continuous line).
Additional file 6: Figure E5. Washout curves from a healthy subject
and a patient with cystic fibrosis fitted to a one-phase exponential decay
model. Cet (norm) = normalised end-tidal SF6 concentration; TO = turnover
number. Panels A and B show washout curves from a healthy subject
and a patient with cystic fibrosis, respectively, fitted to a one-phase
exponential decay model.
Additional file 7: Figure E6. Washout curves from a healthy subject
and a patient with cystic fibrosis fitted to a two-phase exponential decay
model. Cet (norm) = normalised end-tidal SF6 concentration; TO = turnover
number. Panels A and B show washout curves from a healthy subject
and a patient with cystic fibrosis, respectively, fitted to a two-phase
exponential decay model. Goodness of fit (R2) = 0.9973 for healthy
subject and 0.9775 for cystic fibrosis patient.
Additional file 8: Figure E7. Two-compartment lung model. Vslow =
volume of under-ventilated (slow) lung unit; Vfast = volume of over-ventilated
(fast) lung unit; VT = tidal volume; c = proportion of tidal volume reaching fast
lung unit.Competing interests
CEB has received grant funding from Roche-Genentech, Novartis, AZ-
MedImmune, Chiesi and GSK; consultancy fees from Hoffmann-La Roche, AZ,
GSK, Novartis, Chiesi and Merck; and funding for travel to scientific meetings
from Boehringer Ingelheim. SS has received research grants from Chiesi to
study small airway microstructure and has received lecturing fees from Chiesi
and GSK and consultancy fees from Teva. SG has received funding for travel
to scientific meetings from GSK and Chiesi. AH has received a grant from the
National Institute for Health Research to investigate lung clearance index.
Part of this involves a collaboration with Innovision ApS, the manufacturers
of the Innocor gas analyser used in the study. IP has received speaker's fees,
honoraria for attending advisory boards and travel expenses from GSK, AZ,
Boehringer Ingelheim, Napp, Novartis, Aerocrine and Boston Scientific. A
Scadding, MS, A Singapuri, PG, SR and CO have no conflicts of interest to
declare.
Authors’ contributions
SG – Analysed washout curves, derived novel indices, performed statistical
analysis of the data and wrote the manuscript. A Scadding – Recruited
patients, characterised them clinically, and performed washout tests. MS –
Performed washout tests. A Singapuri – Recruited patients and performed
washout tests. PG – Assisted with setting up the inert gas washout system,
and critically appraised the manuscript. CO – Recruited patients and critically
appraised the manuscript. SR – Recruited patients and critically appraised the
manuscript. CEB – Involved in study conception and design, and critically
appraised the manuscript. IP – Involved in study conception and design, and
critically appraised the manuscript. AH – Involved in study conception and
design, and supervised the writing of the manuscript. SS – Involved in study
conception and design, and supervised the writing of the manuscript. All
authors read and approved the final manuscript.Authors’ information
Alex Horsley and Salman Siddiqui are co-senior authors.Acknowledgements
This paper was supported by the National Institute for Health Research
(NIHR) Leicester Respiratory Biomedical Research Unit. The views expressed
are those of the author(s) and not necessarily those of the NHS, the NIHR or
the Department of Health. This work was partly funded by grants-in-aid from
Chiesi Farmaceutici S. P. A. Additional funding was received from the Airway
Disease PRedicting Outcomes through Patient Specific Computational
Modelling (AirPROM) project (funded through an FP7 European Union
grant). Data from cystic fibrosis patients were collected as part of a
separate research project funded by the CF Trust through the UK CF
Gene Therapy Consortium.
Author details
1Institute for Lung Health, University of Leicester, Leicester, UK. 2Department
of Paediatrics, Central Hospital, Skövde, Sweden. 3Manchester Adult Cystic
Fibrosis Centre, Manchester, UK. 4Institute of Inflammation and Repair,
University of Manchester, Manchester, UK. 5Respiratory BRU, Glenfield
Hospital, Groby Road, Leicester LE3 9QP, UK.
Received: 2 December 2013 Accepted: 8 May 2014
Published: 18 May 2014References
1. Seitz AE, Olivier KN, Adjemian J, Holland SM, Prevots R: Trends in
bronchiectasis among medicare beneficiaries in the United States, 2000
to 2007. Chest 2012, 142(2):432–439.
2. Weycker D, Edelsberg J, Oster G, Tino G: Prevalence and economic burden
of bronchiectasis. Clin Pulm Med 2005, 12(4):205–209.
3. McShane PJ, Naureckas ET, Tino G, Strek ME: Non-cystic fibrosis
bronchiectasis. Am J Respir Crit Care Med 2013, 188(6):647–656.
4. De Soyza A, Brown JS, Loebinger MR, Bronchiectasis Research & Academic
Network: Research priorities in bronchiectasis. Thorax 2013, 68(7):695–696.
5. Robinson PD, Goldman MD, Gustafsson PM: Inert gas washout: theoretical
background and clinical utility in respiratory disease. Respiration 2009,
78(3):339–355.
6. Verbanck S, Schuermans D, Noppen M, Van Muylem A, Paiva M, Vincken W:
Evidence of acinar airway involvement in asthma. Am J Respir Crit Care
Med 1999, 159(5 Pt 1):1545–1550.
7. Horsley AR, Gustafsson PM, Macleod KA, Saunders C, Greening AP, Porteous
DJ, Davies JC, Cunningham S, Alton EW, Innes JA: Lung clearance index is
a sensitive, repeatable and practical measure of airways disease in
adults with cystic fibrosis. Thorax 2008, 63(2):135–140.
8. Robinson P, Latzin P, Verbanck S, Hall GL, Horsley A, Gappa M, Thamrin C,
Arets HG, Aurora P, Fuchs S, King GG, Lum S, Macleod K, Paiva M, Pillow J,
Ranganathan S, Ratjen F, Singer F, Sonnappa S, Stocks J, Subbarao P,
Thompson B, Gustafsson PM: Consensus statement for inert gas washout
measurement using multiple and single breath tests. Eur Respir J 2013,
41(3):507–522.
9. Bouhuys A, Lichtneckert S, Lundgren C, Lundin G: Voluntary changes in
breathing pattern and N2 clearance from lungs. J Appl Physiol 1961,
16(6):1039–1042.
10. Horsley A: Lung clearance index in the assessment of airways disease.
Resp Med 2009, 103(6):793–799.
11. Amin R, Subbarao P, Jabar A, Balkovec S, Jensen R, Kerrigan S, Gustafsson P,
Ratjen F: Hypertonic saline improves the LCI in paediatric patients with
CF with normal lung function. Thorax 2010, 65(5):379–383.
12. Amin R, Subbarao P, Lou W, Jabar A, Balkovec S, Jensen R, Kerrigan S,
Gustafsson P, Ratjen F: The effect of dornase alfa on ventilation
inhomogeneity in patients with cystic fibrosis. Eur Respir J 2011,
37(4):806–812.
13. Horsley AR, Davies JC, Gray RD, Macleod KA, Donovan J, Aziz ZA, Bell NJ,
Rainer M, Mt-Isa S, Voase N, Dewar MH, Saunders C, Gibson JS, Parra-Leiton
J, Larsen MD, Jeswiet S, Soussi S, Bakar Y, Meister MG, Tyler P, Doherty A,
Hansell DM, Ashby D, Hyde SC, Gill DR, Greening AP, Porteous DJ, Innes JA,
Boyd AC, Griesenbach U, et al: Changes in physiological, functional and
structural markers of cystic fibrosis lung disease with treatment of a
pulmonary exacerbation. Thorax 2013, 68(6):532–539.
Gonem et al. Respiratory Research 2014, 15:59 Page 9 of 9
http://respiratory-research.com/content/15/1/5914. Rowan SA, Bradley JM, Bradbury I, Lawson J, Lynch T, Gustafsson P, Horsley
A, O’Neill K, Ennis M, Elborn JS: Lung clearance index is a repeatable and
sensitive indicator of radiological changes in bronchiectasis. Am J Respir
Crit Care Med 2014, 189(5):586–592.
15. Verbanck S, Paiva M, Schuermans D, Hanon S, Vincken W, Van Muylem A:
Relationships between the lung clearance index and conductive and
acinar ventilation heterogeneity. J Appl Physiol 2012, 112(5):782–790.
16. Verbanck S, Schuermans D, van Muylem A, Noppen M, Paiva M, Vincken W:
Ventilation distribution during histamine provocation. J Appl Physiol 1997,
83(6):1907–1916.
17. Crawford AB, Makowska M, Paiva M, Engel LA: Convection- and
diffusion-dependent ventilation maldistribution in normal subjects.
J Appl Physiol 1985, 59(3):838–846.
18. Horsley AR, Macleod KA, Robson AG, Lenney J, Bell NJ, Cunningham S,
Greening AP, Gustafsson PM, Innes JA: Effects of cystic fibrosis lung
disease on gas mixing indices derived from alveolar slope analysis.
Respir Physiol Neurobiol 2008, 162(3):197–203.
19. Verbanck S, Paiva M, Schuermans D, Malfroot A, Vincken W, Vanderhelst E:
Acinar and conductive ventilation heterogeneity in severe CF lung
disease: back to the model. Respir Physiol Neurobiol 2013, 188(2):124–132.
20. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R,
Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC,
MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G,
Wanger J, ATS/ERS Task Force: Standardisation of spirometry. Eur Respir J
2005, 26(2):319–338.
21. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R,
Crapo R, Enright P, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R,
Johnson D, Macintyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G:
Standardisation of the measurement of lung volumes. Eur Respir J 2005,
26(3):511–522.
22. Darling RC, Cournand A, Richards DW: Studies on the intrapulmonary
mixture of gases III. An open circuit method for measuring residual air.
J Clin Invest 1940, 19(4):609–618.
23. Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM: Evaluation of
a new definition for chronic Pseudomonas aeruginosa infection in cystic
fibrosis patients. J Cyst Fibros 2003, 2(1):29–34.
24. Venegas JG, Winkler T, Musch G, Vidal Melo MF, Layfield D, Tgavalekos N,
Fischman AJ, Callahan RJ, Bellani G, Harris RS: Self-organized patchiness in
asthma as a prelude to catastrophic shifts. Nature 2005, 434(7034):777–782.
25. Belessis Y, Dixon B, Hawkins G, Pereira J, Peat J, MacDonald R, Field P, Numa
A, Morton J, Lui K, Jaffe A: Early cystic fibrosis lung disease detected by
bronchoalveolar lavage and lung clearance index. Am J Respir Crit Care
Med 2012, 185(8):862–873.
26. Martínez-García MA, Soler-Cataluña JJ, Perpiñá-Tordera M, Román-Sánchez P,
Soriano J: Factors associated with lung function decline in adult patients
with stable non-cystic fibrosis bronchiectasis. Chest 2007, 132(5):1565–1572.
27. Verbanck S, Thompson BR, Schuermans D, Kalsi H, Biddiscombe M,
Stuart-Andrews C, Hanon S, Van Muylem A, Paiva M, Vincken W,
Usmani O: Ventilation heterogeneity in the acinar and conductive
zones of the normal ageing lung. Thorax 2012, 67(9):789–795.
doi:10.1186/1465-9921-15-59
Cite this article as: Gonem et al.: Lung clearance index in adults with
non-cystic fibrosis bronchiectasis. Respiratory Research 2014 15:59.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
